Afatinib vs Pyrotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR/HER1, HER2, HER4 · full Non-Small Cell Lung Cancer pipeline
Afatinib · Gilotrif
Marketed by Boehringer Ingelheim
NCT00949650 · Phase 3 · completed
The study randomly assigned 345 participants to afatinib or active chemotherapy, but it was open-label rather than blinded. Its hard clinical primary endpoint, centrally assessed progression-free survival, was statistically significantly better with afatinib, but the lack of blinding limits the strength of the evidence.
Next expected readout: December 2026 · NCT04413201 (registry estimate)
Reported efficacy
Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7) (met)
Result source: NCT01121393
Pyrotinib
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
NCT04447118 · Phase 3 · completed
The study randomly assigned 151 participants to pyrotinib or active treatment with docetaxel, with the primary endpoint assessed by an independent committee blinded to treatment assignment. Because results for the progression-free survival comparison have not been posted, the trial provides limited evidence at this time despite its randomized design.
Next expected readout: December 2026 · NCT05482568 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Afatinib | Pyrotinib |
|---|---|---|
| PFS, median | 11.2 vs 6.9vs Pemetrexed/CisplatinNCT0094965022 other results
| —Not posted · NCT04447118 |
| OS, median | 28.2 vs 28.2vs Pemetrexed/CisplatinNCT0094965010 other results
| —Not posted · NCT04447118 |
| ORR | 67.8% vs 23%vs Gemcitabine / CisplatinNCT0112139314 other results
| —Not posted · NCT04447118 |
| Duration of response, median | 9.7 vs 4.3vs Gemcitabine / CisplatinNCT011213936 other results
| —Not posted · NCT04447118 |
PFS, median
- Afatinib
- 11.2 vs 6.9vs Pemetrexed/CisplatinNCT00949650
22 other results
- 11.0 vs 5.6 NCT01121393
- 2.6 vs 1.9 NCT01523587
- 5.5 vs 2.9 NCT01085136
- 3.3 vs 1.1 NCT00656136
- 3.1 NCT01085136
- 15.4 NCT01814553
- 9.9 NCT01814553
- 10.9 NCT02208843
- 1.9 NCT00796549
- 10.2 NCT00525148
- 4.6 NCT01090011
- 2.8 NCT02597946
- 0.9 NCT01003899
- 3.7 NCT00730925
- 2.7 NCT01090011
- 2.9 NCT01090011
- 2.1 NCT03157089
- 3.3 NCT03157089
- 3.7 NCT02369484
- 5.9 NCT02364609
- 1.4 NCT02364609
- 4.2 NCT01090011
- Pyrotinib
- —Not posted · NCT04447118
OS, median
- Afatinib
- 28.2 vs 28.2vs Pemetrexed/CisplatinNCT00949650
10 other results
- 23.1 vs 23.5 NCT01121393
- 7.8 vs 6.8 NCT01523587
- 12.3 vs 13.1 NCT01085136
- 18.4 NCT00711594
- 11.6 NCT00796549
- 26.8 NCT00525148
- 10.0 NCT02597946
- 8.8 NCT03157089
- 6.1 NCT03157089
- 12.9 NCT02369484
- Pyrotinib
- —Not posted · NCT04447118
ORR
- Afatinib
- 67.8% vs 23%vs Gemcitabine / CisplatinNCT01121393
14 other results
- 31.2% vs 13.2% NCT01085136
- 8.5% NCT01085136
- 50% NCT02208843
- 13% NCT00796549
- 62% NCT00525148
- 0% NCT02597946
- 0% NCT01003899
- 2% NCT00730925
- 16.7% NCT03157089
- 8.3% NCT03157089
- 13% NCT00796549
- 11.6% NCT00796549
- 17% NCT02364609
- 25% NCT02364609
- Pyrotinib
- —Not posted · NCT04447118
Duration of response, median
- Afatinib
- 9.7 vs 4.3vs Gemcitabine / CisplatinNCT01121393
6 other results
- 10.5 NCT00796549
- 17.6 NCT00525148
- 9 NCT01090011
- 3.9 NCT01090011
- 5.8 NCT01090011
- 0 NCT01090011
- Pyrotinib
- —Not posted · NCT04447118
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Pyrotinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Afatinib: 4 of 4 rows · Pyrotinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Afatinib |
|---|---|
| Dropout rate | n/a: no completion milestone40 mga NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 32 more results—50 mg/Day NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone50 mg/Day NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —40 mg NCT00525148 · Phase 2 —50 mg NCT00525148 · Phase 2 100%40mg NCT01121393 · Phase 3 n/a: no completion milestone NCT01523587 · Phase 3 n/a: no completion milestone40 mg NCT02208843 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT01853826 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT01953913 · Phase 3 · registry result, not featured evidence 0%40 mg NCT02044380 · Phase 3 · registry result, not featured evidence 28%Afatinib Monotherapy (Part A) NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy —Afatinib Plus Paclitaxel (Part B) NCT01085136 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone40 mg NCT02597946 · Phase 2 · registry result, not featured evidence 0% NCT02369484 · Phase 2 · registry result, not featured evidence n/a: no completion milestone40 mg NCT00711594 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg NCT00711594 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg NCT00711594 · Phase 2 · registry result, not featured evidence n/a: no completion milestone20 mg NCT00711594 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg NCT00796549 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg NCT00730925 · Phase 2 · registry result, not featured evidence n/a: no completion milestone40 mg NCT01003899 · Phase 2 · registry result, not featured evidence 0%Arm I (Afatinib Dimaleate, Pembrol NCT02364609 · Phase 1 · registry result, not featured evidence · combination 0%Arm II (Pembrolizumab, Afatinib Di NCT02364609 · Phase 1 · registry result, not featured evidence · combination —Afa40+Ctx250 NCT01090011 · Phase 1 · registry result, not featured evidence · combination —Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination —Afa40 Mono NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy —Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 0% NCT01074177 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 12.2%40 mga NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 32 more results—50 mg/Day NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 13.1%50 mg/Day NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —40 mg NCT00525148 · Phase 2 —50 mg NCT00525148 · Phase 2 9.9%40mg NCT01121393 · Phase 3 17.1% NCT01523587 · Phase 3 20%40 mg NCT02208843 · Phase 4 · registry result, not featured evidence 12.9% NCT01853826 · Phase 3 · registry result, not featured evidence 3.7% NCT01953913 · Phase 3 · registry result, not featured evidence —40 mg NCT02044380 · Phase 3 · registry result, not featured evidence 19.3%Afatinib Monotherapy (Part A) NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy —Afatinib Plus Paclitaxel (Part B) NCT01085136 · Phase 3 · registry result, not featured evidence · combination 22.2%40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 22.7%40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 41.7%40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 33.3%30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination —40 mg NCT02597946 · Phase 2 · registry result, not featured evidence — NCT02369484 · Phase 2 · registry result, not featured evidence 0%40 mg NCT00711594 · Phase 2 · registry result, not featured evidence 0%50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 25.8%50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 33.3%20 mg NCT00711594 · Phase 2 · registry result, not featured evidence 5%50 mg NCT00796549 · Phase 2 · registry result, not featured evidence —50 mg NCT00730925 · Phase 2 · registry result, not featured evidence 17%40 mg NCT01003899 · Phase 2 · registry result, not featured evidence —Arm I (Afatinib Dimaleate, Pembrol NCT02364609 · Phase 1 · registry result, not featured evidence · combination —Arm II (Pembrolizumab, Afatinib Di NCT02364609 · Phase 1 · registry result, not featured evidence · combination —Afa40+Ctx250 NCT01090011 · Phase 1 · registry result, not featured evidence · combination —Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination —Afa40 Mono NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy —Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination — NCT01074177 · Phase na · registry result, not featured evidence |
| Serious AEs | 31.4%40 mga NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 32 more results34.9%50 mg/Day NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —50 mg/Day NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 30%40 mg NCT00525148 · Phase 2 44.4%50 mg NCT00525148 · Phase 2 16.7%40mg NCT01121393 · Phase 3 44.4% NCT01523587 · Phase 3 35%40 mg NCT02208843 · Phase 4 · registry result, not featured evidence 43.8% NCT01853826 · Phase 3 · registry result, not featured evidence 30.3% NCT01953913 · Phase 3 · registry result, not featured evidence 21.4%40 mg NCT02044380 · Phase 3 · registry result, not featured evidence 40.8%Afatinib Monotherapy (Part A) NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy 40.3%Afatinib Plus Paclitaxel (Part B) NCT01085136 · Phase 3 · registry result, not featured evidence · combination 55.6%40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 22.7%40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 33.3%40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 75%30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 33.3%40 mg NCT02597946 · Phase 2 · registry result, not featured evidence 38.5% NCT02369484 · Phase 2 · registry result, not featured evidence 0%40 mg NCT00711594 · Phase 2 · registry result, not featured evidence 33.3%50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 25.8%50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 33.3%20 mg NCT00711594 · Phase 2 · registry result, not featured evidence 50.7%50 mg NCT00796549 · Phase 2 · registry result, not featured evidence 46.3%50 mg NCT00730925 · Phase 2 · registry result, not featured evidence 40.5%40 mg NCT01003899 · Phase 2 · registry result, not featured evidence 0%Arm I (Afatinib Dimaleate, Pembrol NCT02364609 · Phase 1 · registry result, not featured evidence · combination 40%Arm II (Pembrolizumab, Afatinib Di NCT02364609 · Phase 1 · registry result, not featured evidence · combination 75%Afa40+Ctx250 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 50%Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 32.4%Afa40 Mono NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy 41.7%Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 12.5% NCT01074177 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 40 mga diarrhoea 94.3% rash 63.3% paronychia 57.6% NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 31 more results50 mg/Day diarrhoea 85.6% (placebo 9.2%) rash 63.6% (placebo 11.8%) paronychia 33.6% (placebo 0.5%) NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 40 mg diarrhoea 73.3% rash 30% paronychia 23.3% NCT02208843 · Phase 4 · registry result, not featured evidence diarrhoea 49.7% rash 29.9% paronychia 17.7% NCT01853826 · Phase 3 · registry result, not featured evidence diarrhoea 89.3% rash 70.8% paronychia 50.1% NCT01953913 · Phase 3 · registry result, not featured evidence 40 mg diarrhoea 92.9% decreased appetite 42.9% nausea 42.9% NCT02044380 · Phase 3 · registry result, not featured evidence diarrhoea 83.5% rash 54.5% paronychia 29.6% NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy diarrhoea 53.7% alopecia 35.1% asthenia 35.1% NCT01085136 · Phase 3 · registry result, not featured evidence · combination 40 mg diarrhoea 88.9% nausea 66.7% dry skin 44.4% NCT01814553 · Phase 3 · registry result, not featured evidence · combination 40 mg diarrhoea 81.8% constipation 50% dermatitis acneiform 36.4% NCT01814553 · Phase 3 · registry result, not featured evidence · combination 40 mg + 200 mg diarrhoea 91.7% decreased appetite 50% rash 41.7% NCT03157089 · Phase 2 · registry result, not featured evidence · combination 30 mg + 200 mg diarrhoea 58.3% dermatitis acneiform 41.7% fatigue 33.3% NCT03157089 · Phase 2 · registry result, not featured evidence · combination 40 mg diarrhoea 66.7% rash 33.3% anaemia 22.2% NCT02597946 · Phase 2 · registry result, not featured evidence diarrhea 84.6% paronyclia 38.5% erythema multiforme 30.8% NCT02369484 · Phase 2 · registry result, not featured evidence 40 mg nausea 100% rash 100% stomatitis 100% NCT00711594 · Phase 2 · registry result, not featured evidence 50 mg diarrhoea 100% dry skin 83.3% acne 50% NCT00711594 · Phase 2 · registry result, not featured evidence 50 mg diarrhoea 93.5% rash 85.5% paronychia 67.7% NCT00711594 · Phase 2 · registry result, not featured evidence 20 mg dry skin 100% malaise 100% rash 100% NCT00711594 · Phase 2 · registry result, not featured evidence 50 mg diarrhoea 76.8% rash 73.9% mucosal inflammation 29% NCT00796549 · Phase 2 · registry result, not featured evidence 50 mg diarrhoea 87.8% rash 68.3% decreased appetite 53.7% NCT00730925 · Phase 2 · registry result, not featured evidence 40 mg rash 76.2% diarrhoea 61.9% decreased appetite 42.9% NCT01003899 · Phase 2 · registry result, not featured evidence anemia 83.3% diarrhea 83.3% anorexia 66.7% NCT02364609 · Phase 1 · registry result, not featured evidence · combination nausea 100% diarrhea 80% anemia 60% NCT02364609 · Phase 1 · registry result, not featured evidence · combination Afa40+Ctx250 fatigue 75% nausea 75% chest pain 50% NCT01090011 · Phase 1 · registry result, not featured evidence · combination Afa40+Ctx500 rash 84.1% diarrhoea 73% skin fissures 61.9% NCT01090011 · Phase 1 · registry result, not featured evidence · combination Afa40 Mono diarrhoea 73% fatigue 43.2% rash 37.8% NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy Afa40+Ctx500 rash 47.2% skin fissures 44.4% fatigue 38.9% NCT01090011 · Phase 1 · registry result, not featured evidence · combination head/headache 87.5% dysphagia 83.3% infection gr0-2 neut, oral cavity 54.2% NCT01074177 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 30 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Afatinib
show 4 more results
show 1 more result
show 3 more results
show 12 more results
show 5 more results
show 6 more results
show 17 more results
show 6 more results
+ 38 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afatinib's landscape · Pyrotinib's landscape